UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)

BMC cancer, 2017-07, Vol.17 (1), p.493-493, Article 493

2017

Volltextzugriff (PDF)

Systemic adjuvant therapies in renal cell carcinoma

Oncology reviews, 2012-10, Vol.6 (2), p.e18-e18

2012

Volltextzugriff (PDF)

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Expert review of anticancer therapy, 2020-06, Vol.20 (6), p.491-501

2020

Volltextzugriff (PDF)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Annals of oncology, 2020-10, Vol.31 (10), p.1415-1416

2020

Volltextzugriff (PDF)

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer

European journal of cancer (1990), 2020-11, Vol.140, p.140-146

2020

Volltextzugriff (PDF)

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma

Journal of clinical oncology, 2011-11, Vol.29 (33), p.e803-e805

2011

Volltextzugriff (PDF)

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

European urology, 2015-07, Vol.68 (1), p.147-153

2015

Volltextzugriff (PDF)

Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16023-e16023

2019

Volltextzugriff (PDF)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Drugs in R&D, 2017-12, Vol.17 (4), p.585-596

2017

Volltextzugriff (PDF)

A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4502-4502

2018

Volltextzugriff (PDF)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Drugs in R&D, 2018-06, Vol.18 (2), p.163-163

2018

Volltextzugriff (PDF)

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

European urology oncology, 2019-11, Vol.2 (6), p.699-707

2019

Volltextzugriff (PDF)

A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.471-471

2012

Volltextzugriff (PDF)

Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.326-326

2016

Volltextzugriff (PDF)

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

Future oncology (London, England), 2019-04, Vol.15 (10), p.1115-1123

2019

Volltextzugriff (PDF)

When a thymic carcinoma “becomes” a GIST

Lung cancer (Amsterdam, Netherlands), 2013-04, Vol.80 (1), p.106-108

2013

Volltextzugriff (PDF)

Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

BJU international, 2015-05, Vol.115 (5), p.764-771

2015

Volltextzugriff (PDF)

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15552-e15552

2016

Volltextzugriff (PDF)

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5030-5030

2017

Volltextzugriff (PDF)

Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.210-210

2016

Volltextzugriff (PDF)

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.230-230

2017

Volltextzugriff (PDF)

A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis

Acta bio-medica de l'Ateneo Parmense, 2012-08, Vol.83 (2), p.88-94

2012

Volltextzugriff (PDF)

Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16045-e16045

2015

Volltextzugriff (PDF)

Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16031-e16031

2016

Volltextzugriff (PDF)

Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.303-303

2015

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(55)
Reviews
(1)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(19)
Male
(17)
Oncology
(15)
Aged
(11)
Middle Aged
(11)
Treatment Outcome
(11)
Retrospective Studies
(10)
Aged, 80 And Over
(8)
Female
(8)
Adult
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Castration-Resistant Prostate Cancer
(6)
Metastasis
(6)
Prostatic Neoplasms, Castration-Resistant - Drug Therapy
(6)
Cancer Therapies
(5)
Patients
(5)
Renal Cell Carcinoma
(5)
Biological And Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)

Systemic adjuvant therapies in renal cell carcinoma

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study

Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

When a thymic carcinoma “becomes” a GIST

Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study

Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study

A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis

Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP)

Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial)

Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC

Suchergebnisse filtern